Pope Mason
- "The drug may enhance hypoglycemic agents by slowing their clearance, heightening the risk of symptomatic hypoglycemia in insulin- or sulfonylurea-treated patients. Clinically consequential interactions center on […]"
View
Active 3 months, 2 weeks ago